Activation of LYN kinase is associated with imatinib-resistance in CML patients

Activation of LYN kinase is associated with resistance to imatinib (Gleevec) in patients with chronic myelogenous leukemia (CML), researchers report in the June 24 online issue of the Journal of the National Cancer Institute . Imatinib is the standard therapy for newly diagnosed CML patients. ...

Combination of 2 novel anti-cancer agents may help fight CML resistant to current therapy

Virginia Commonwealth University Massey Cancer Center researchers have identified that a combination of novel anti-cancer compounds is able to kill chronic myelogenous leukemia cells previously resistant to conventional forms of therapy. Chronic myelogenous leukemia, or CML, is a cancer of the ...

ChemGenex's omacetaxine may provide first viable treatment option for highly resistant form of CML

MELBOURNE, Australia, and MENLO PARK, California U.S.A. (June 1st, 2009) ChemGenex Pharmaceuticals Limited (ChemGenex) (ASX:CXS) announced that the latest data from its pivotal study of omacetaxine in patients with T315I-positive chronic myeloid leukemia (CML) was the subject of an oral presentat...

Early Phase II results show bosutinib safe, effective for CML

ATLANTA - A new drug for chronic myelogenous leukemia works for patients who have developed resistance to frontline therapy and causes fewer side effects than other medications in its class, a research team led by scientists at The University of Texas M. D. Anderson Cancer Center reports at the 49...

New Strategy for the Treatment of CML

Virginia Commonwealth University Massey Cancer Center researchers have identified an approach to enhance the activity of a new //anti-cancer agent that has already shown impressive efficacy in the treatment of chronic myelogenous leukemia. Chronic myelogenous leukemia, or CML, is a cancer of th...

Finding key to cancer drug Gleevec's limitations

...Until imatinib was introduced in 2001, people with cml faced a grim prognosis, with few surviving five ye... that prospect, allowing 95 percent of people with cml to survive five years. Yet it soon became clear...hat certain cells that set events in motion toward cml are able to resist the drug. "The mouse model ...

Janet Rowley, MD, A Researcher Funded by The Leukemia & Lymphoma Society, Receives Presidential Medal of Freedom

...emia (CML) was an abnormal translocation of two chromosomes. Her discovery was a key step in the eventual discovery of Gleevec, a targeted therapy for cml patients. Rowley, 84, is the Blum-Riese Distinguished Service Professor of Medicine, Molecular Genetics and Cell Biology and Human Genetics at...

Regence Adds New, Diverse Talent to Board of Directors

...ent and chief financial officer for Nordstrom, Inc. Before joining Nordstrom, he held leadership positions in the retail industry at companies such as cml Group, Lids Corporation and May Department Stores. Koppel serves on the board of Big Brothers Big Sisters of King County. He earned his undergraduate ...

Cepheid Announces European Release of Improved Test for BCR-ABL Chromosomal Translocation Associated With Chronic Myelogenous Leukemia (CML)

...system. We will continue to extend the many unique benefits of the GeneXpert System across multiple markets and testing applications." Worldwide, cml affects 1 to 2 people per 100,000 annually.(1) The Europe Against Cancer Program practice guidelines, for management of patients with CML, call for us...

Enhancing the effects of the drug used to treat chronic myeloid leukemia

...no Calabretta, observed that for several different cml cell lines and primary cells, although imatinib me...ference enhanced imatinib mesylateinduced death of cml cell lines, primary cml cells, and...

CML in Medical Technology

Launch of Highly Targeted Cancer Treatment Tasigna(R) (nilotinib) Offers Potential Lifeline to Ph+ CML Patients Intolerant or Resistant to Existing Therapies, Including Glivec(R) (imatinib)

FRIMLEY, England, May 20 /PRNewswire-FirstCall/ -- - Tasigna(R) (nilotinib) Effective in 77% of Patients Resistant or Intolerant to Prior Treatment in the Chronic (Early) Phase of Chronic Myeloid Leukaemia (CML)(1) - Highly Targeted Nature of Tasigna(R) Tackles the Root Cause of CML Whilst...

Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types

...e potential hazard to the fetus. In adult Ph+ cml patients, severe (NCI Grades 3/4) lab abnormalitie...reactions in 2.4% to 5% of adult patients with Ph+ cml and for adverse reactions in 5% of KIT+ GIST patie...ts of Gleevec tablets The majority of adult Ph+ cml patients who received Gleevec in clinical studies ...

Creighton Medical Laboratories First to Offer New Cancer Test

...rvices. Through its affiliation with Creighton University School of Medicine, an institution with an international reputation for medical research, cml helps physicians, clinics, nursing facilities and hospitals it serves deliver advanced and more effective patient-care. About Creighton Universi...

Synvista Therapeutics Announces Termination of Clinical Trials of Alagebrium and SYI-2074 and Provides Business Update

...cardiovascular complications. These patients may benefit from a particular formulation of vitamin E. The Company is also developing a kit to measure cml (carboxy-methyllysine), another potential cardiovascular risk marker. For more information, please visit the Company's Web site at www.synvista....

Synvista Therapeutics Announces Published Data Demonstrating Elevation of Carboxymethyl-Lysine (CML) Is Associated with Decline in Renal Function and Arterial Stiffness in Older Adults

... Synvista Therapeutics Technology Provided cml Biomarker Data for Studies MONTVALE, N.J....inical diagnostic assay as it prepares to submit a cml kit for 510(k) clearance in the second half of 200...tant next step in our understanding of the role of cml in an elderly population, and they provide physici...

Synvista Therapeutics Announces First Dosing of SYI-2074 in Clinical Trial for Psoriasis

...diovascular complications. These patients may benefit from a particular formulation of vitamin E. The Company is also developing a test kit to measure cml (carboxy-methyllysine), another potential cardiovascular risk marker. Synvista Therapeutics is developing oral antioxidant drugs to treat the...

Video: Tasigna(R) Demonstrates Rapid Response as Initial Therapy in Life-Threatening Form of Leukemia

... 96% of Tasigna patients and reduction of abnormal cml protein by six months Larger front-line Ph...sylate) tablets* is the standard treatment for Ph+ cml and rapidly transformed the treatment of cml when it was introduced in 2001. An ongoing Phase I...

More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies

...w-up is limited to 5 years. Gleevec is also indicated for patients with Ph+ cml in blast crisis (BC), accelerated phase (AP), or in the chronic phase (CP) ... Common side effects of Gleevec tablets The majority of adult Ph+ cml patients who received Gleevec in clinical studies experienced adverse react...

Premier Research Honored as 'Clinical Research Team of the Year' at 2008 GCPj Awards

...t on achieving longer-term objectives of advancing drug development. Covering seven countries and nine time zones, Premier Research's Global Phase 2 cml Study Team provided their sponsor innovative solutions in a tight timeframe through streamlined communication, unwavering dedication, and extraordinar...

Early Data Show Potential for Imatinib Mesylate Tablets to Treat Life-Threatening Form of Pulmonary Artery Disease

...o indicated for the treatment of patients with Ph+ cml in blast crisis (BC), accelerated phase (AP), or i...stromal tumors (GIST); pediatric patients with PH+ cml in the chronic phase who are newly diagnosed or wh... the potential hazard to the fetus. In adult Ph+ cml patients, severe (NCI Grades 3/4) lab abnormalitie...

CML in Medical Definition

Hematopathology

...mphoma ( Hodgkin's disease , NHL ) • LPD • Myeloma ( Multiple myeloma , Extramedullary plasmacytoma ) Myeloid : Myeloid leukemia ( AML , cml ) • MPD Ph- ( Essential thrombocytosis , Polycythemia vera , Myelofibrosis ) • MDS • Neutropenia Red blood cells / anemia / hemoglobino...

Pathology

...mphoma ( Hodgkin's disease , NHL ) • LPD • Myeloma ( Multiple myeloma , Extramedullary plasmacytoma ) Myeloid : Myeloid leukemia ( AML , cml ) • MPD Ph- ( Essential thrombocytosis , Polycythemia vera , Myelofibrosis ) • MDS • Neutropenia Red blood cells / anemia / hemoglobino...

CML in Medical Dictionary

Cml

Chronic myelogenous (or myeloid) leukemia ( CML ), also known as chronic granulocytic leukemia (CGL), is a form of leukemia characterized by the increased and unregulated growth of predominantly myeloid cells in the bone marrow... CML Innovative Technologies provides its customers wit...

Granulocyte

... Original Article from The New England Journal of Medicine -- Granulocyte -Macrophage Progenitors as Candidate Leukemic Stem Cells in Blast-Crisis cml Original Article from The New England Journal of Medicine -- Mutations in the Gene for the Granulocyte Colony-Stimulating-Factor Receptor in Pat...

CML in Biological News

St. Jude finds factors that accelerate resistance to targeted therapy in lymphoblastic leukemia

...ctive treatments for patients who are not helped by current therapies. cml and an aggressive form of ALL share the same critical mutationthe Philadelp...cells lack a tumor-suppressor gene called Arf, which is normally present in cml cells at the time the disease is first diagnosed, said Sherr. Stripped of t...

JCI table of contents: Aug. 16, 2007

...drug that can target dasatinib- and imatinib-resitant BCR-ABL is currently in clinical trials. The authors therefore suggest that rather than treating cml patients with the drugs that target BCR-ABL sequentially, they should receive all the drugs when they are first diagnosed with the disease so that the...

New strategy rapidly identifies cancer targets

...y on the market, including Gleevec, which Druker pioneered for treatment of chronic myelogenous leukemia. Since its approval in 2001, Gleevec has made cml a much more manageable disease. A new drug to inhibit JAK3 is already in development elsewhere, and, eventually, Druker sees a market filled with...

CML in Biological Technology

FDA Approves New SPRYCEL(R) (Dasatinib) Product Labeling for Patients with Chronic-Phase CML

- Labeling Now Includes Lower Once-Daily Starting Dose and Data from First Randomized Trial of SPRYCEL and Gleevec(R)*(imatinib mesylate) - PRINCETON, N.J., Nov. 8 /PRNewswire-FirstCall/ -- Bristol-Myers Squibb Company (NYSE: BMY ) today announced that the U.S. Food and Drug Administration ...

Quest Diagnostics to Present Genomic Studies Related to New Testing Techniques for Leukemia and Prostate Cancer at 2009 ASCO Meeting

... with CML. We are also hopeful that our studies on cml may provide the basis for one day developing comme...ict which patients may not respond to conventional cml therapy, so they may begin alternative treatment o...tics demonstrated that 73 percent of patients with cml who are resistant to treatment with imatinib exhib...

Synvista Therapeutics Announces Restructuring of Dividend Obligation to Preferred Stockholders and Decision to Delist from NYSE Alternext and Terminate SEC Registration of Common Stock

...EK(TM) clinical diagnostic test for Hp2-2 diabetes, and its test to measure cml (carboxy-methyllysine), another potential cardiovascular risk marker. ... formulation of vitamin E. The Company is also developing a kit to measure cml (carboxy-methyllysine), another potential cardiovascular risk marker. ...

Synvista Therapeutics Announces Progress in Phase 2 Clinical Trial Program for Alagebrium

...r cardiovascular complications. These patients may benefit from a particular formulation of Vitamin E. The Company is also developing a kit to measure cml (carboxy-methyllysine), another potential cardiovascular risk marker. Synvista Therapeutics is developing alagebrium, a proposed breaker of advan...

Synvista Therapeutics Announces 510(k) Submission for Its HAPTOCHEK(TM) Test Kit

...cardiovascular complications. These patients may benefit from a particular formulation of vitamin E. The Company is also developing a kit to measure cml (carboxy-methyllysine), another potential cardiovascular risk marker. Synvista Therapeutics is developing oral antioxidant drugs to treat the...

Synvista Therapeutics Announces Data Further Demonstrating the Value of Haptoglobin Genotyping in Diabetic Patients During AHA Meeting

...r cardiovascular complications. These patients may benefit from a particular formulation of vitamin E. The Company is also developing a kit to measure cml (carboxy-methyllysine), another potential cardiovascular risk marker. Synvista Therapeutics is developing oral antioxidant drugs to treat the HDL dy...

Synvista Therapeutics to Present at the Rodman & Renshaw 10th Annual Healthcare Conference

...r cardiovascular complications. These patients may benefit from a particular formulation of Vitamin E. The Company is also developing a kit to measure cml (carboxy-methyllysine), another potential cardiovascular risk marker. Synvista Therapeutics is developing oral antioxidant drugs to treat the HDL dy...

Synvista Therapeutics Posts Letter to Stockholders on Web Site

...ker. Last year, researchers published reports that cml may predict outcomes in patients with heart failur...ult of accumulating data on the connection between cml levels and cardiovascular outcomes and the progres...opment program, we have begun to commercialize our cml assay. To date, a licensee has sold more than 6,00...

Gleevec Receives FDA Priority Review as First Therapy to Reduce Recurrence of Gastrointestinal Stromal Tumors After Surgery

...o indicated for the treatment of patients with Ph+ cml in blast crisis (BC), accelerated phase (AP), or i... the potential hazard to the fetus. In adult Ph+ cml patients, severe (NCI Grades 3/4) lab abnormalitie...entages in 4 studies among adult patients with Ph+ cml in blast crisis, accelerated phase, and chronic ph...

SGX Pharmaceuticals Submits Investigational New Drug Application for SGX393

...d refractory chronic myelogenous leukemia (CML). The standard of care for cml is Gleevec(R). Although Gleevec is a highly effective front-line therapy fo...bit is the T315I mutant. Neither Gleevec nor the two more recently approved cml treatments, Sprycel(R) and Tasigna(R), inhibit the T315I mutant. SGX393 inh...